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The study protocol was approved by local institutional
review boards. All patients gave written informed consent.
Two hundred seventy-nine patients (201 men, 78 women;
mean age, 58 years) with iliac artery disease were ran-
domly assigned to undergo primary stent placement (143
patients) or percutaneous transluminal angioplasty (PTA)
with selective stent placement in cases in which the resid-
ual mean pressure gradient was greater than 10 mm Hg
across the treated site (136 patients). Before and at 3, 12,
and 24 months and 5–8 years after treatment, all patients
underwent assessment, which included duplex ultrasonog-
raphy (US), ankle-brachial index (ABI) measurement,
Fontaine classification of symptoms, and completion of the
Rand 36-Item Health survey for quality-of-life assessment.
Treatment was considered successful for symptoms if
symptoms increased at least one Fontaine grade, for ABI if
ABI increased more than 0.10, for patency if peak systolic
velocity ratio at duplex US was less than 2.5, and for
quality of life if the RAND 36-Item Health Survey score
increased more than 15 points. Effects of both treatments
on symptoms, quality of life, patency, and ABI were com-
pared by using survival analyses.
Results: Patients who underwent PTA and selective stent place-
ment had better improvement of symptoms (hazard ratio
[HR], 0.8; 95% confidence limits [CLs]: 0.6, 1.0) than did
patients treated with primary stent placement, whereas
ABI (HR, 0.9; 95% CLs: 0.7, 1.3), iliac patency (HR, 1.3;
95% CLs: 0.8, 2.1), and score for quality of life for nine
survey dimensions did not support a difference between
treatment groups.
Conclusion: Patients treated with PTA and selective stent placement in
the iliac artery had a better outcome for symptomatic
success compared with patients treated with primary stent
placement, whereas data about iliac patency, ABI, and
quality of life did not support a difference between groups.
 RSNA, 2005
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In 1964, Dotter and Judkins pub-lished an article in Circulation (1964;30:654–670) that was later re-
printed in Radiology (1) in which they
proposed the use of percutaneous trans-
luminal angioplasty (PTA) to improve
signs and symptoms of peripheral arte-
rial disease (PAD) in patients. In the
past few decades, endovascular treat-
ment of iliac artery lesions has become
safe and effective. When stent place-
ment was introduced in the 1990s, se-
lective stent placement soon became an
accepted treatment for unsatisfactory
PTA results or occlusion. This change in
medical practice was based on results in
short-term nonrandomized studies.
Nowadays, there is a tendency to place
stents primarily. There is, however,
limited evidence to prove which of the
different endovascular treatment strate-
gies is best for iliac artery lesions. Most
studies on this subject were cohort stud-
ies, and they provided only short- or
midterm results. The long-term effects
of stent placement are unknown. The
best way to study these effects is in a
randomized trial. To the best of our
knowledge, the only study in which ran-
domization was used for endovascular
treatment in the iliac arteries is the
Dutch Iliac Stent Trial (DIST). In the
DIST study, patients with iliac artery
lesions were randomized to undergo
primary stent placement or PTA with
selective stent placement. Short-term
(3-month) and midterm (12- and 24-
month) results have been published
(2,3). Thus, the purpose of our current
study was to determine the long-term
results of the prospective DIST.
Materials and Methods
General Information
Methods have been described exten-
sively in previous articles (2,3). Accord-
ingly, we present a short description of
the DIST study with a detailed descrip-
tion of methods in regard to the long-
term follow-up. The study protocol was
approved by the local institutional re-
view boards. All patients gave written
informed consent. The long-term fol-
low-up assessment was financially sup-
ported by Cordis, Roden, the Nether-
lands. Authors had full control over the
data and analyses, without any interfer-
ence of Cordis.
Study Population
Two hundred seventy-nine patients
(201 men, 78 women; mean age, 58
years) with intermittent claudication or
critical ischemia caused by stenosis or
short occlusion ( 5 cm) in the iliac
arteries were examined in the depart-
ments of vascular surgery in six study
centers (see Acknowledgments) from
November 1993 to November 1996 and
were included in the study. Radiologists
involved included three authors of this
article (J.H.S., T.T.C.O., W.P.T.M.M.),
and all had at least 5 years of experience
with interventional procedures at the
start of the trial. Inclusion criteria for
patients were (a) clinical signs and
symptoms of PAD—such as pain local-
ized in the buttock, upper area of the
leg, or the calf—and/or reduced pulsa-
tion of the femoral artery and/or re-
duced ankle-brachial index (ABI);
(b) significant stenosis in the common
or external iliac artery—as evident by
an arterial diameter reduction of more
than 50% at angiography—and/or a
peak systolic velocity ratio of more than
2.5 and/or a mean pressure gradient of
more than 10 mm Hg over the stenosis
(with intraarterial vasodilation); and
(c) stenosis of 10 cm or less in length or
occlusion of 5 cm or less in length that
allowed passage with a guidewire.
Other than the 279 patients, 86 pa-
tients were excluded for the following
reasons: unwillingness to participate
(n  27), protocol restrictions (n  59)
(21 patients had stenoses extending into
the distal aorta; in 20, results of angiog-
raphy could not confirm the extent of
disease as assessed with duplex ultra-
sonography [US]; eight had stenosis of
more than 10 cm in length or occlusion
of more than 5 cm; in seven patients,
the lesion could not be passed with a
guidewire; and three patients had ex-
tensive diffuse atherosclerotic changes
of the vessels for which PTA or stent
placement that, according to the proto-
col, would have been insufficient). In
patients with multiple unilateral or bilat-
eral iliac stenoses, all lesions were as-
signed to receive the same treatment.
Multiple stenoses localized in one arte-
rial segment (ie, common iliac artery or
external iliac artery) were classified as a
single lesion. For the survival analyses,
we used only one lesion per person: In
cases in which more than one lesion was
present per person, the most severe le-
sion was selected on the basis of symp-
toms and angiographically determined
percentage of stenosis or, when this
was not sufficient for discrimination, on
the basis of the peak systolic velocity
ratio determined at duplex US.
Patients were randomly assigned to
undergo either primary stent placement
(group 1, 143 patients with 187 lesions
in 181 legs) or primary PTA with selec-
tive stent placement, such as in cases in
which the residual mean pressure gradi-
ent was greater than 10 mm Hg (group
2, 136 patients with 169 lesions in 164
legs). In group 2, 59 (43%) of 136 pa-
tients (65 [38%] of 169 lesions) needed
stent placement. Comparison of the risk
profile in both groups did not reveal dif-
ferences (Table 1) (2).
In patients who underwent primary
stent placement, a long 7-F introducer
sheath was placed across the targeted




ABI  ankle-brachial index
CL  confidence limit
DIST  Dutch Iliac Stent Trial
HR  hazard ratio
PAD  peripheral arterial disease
PTA  percutaneous transluminal angioplasty
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segment. The stent (Palmaz; Johnson
and Johnson Interventional Systems,
Warren, NY) was mounted by hand on
a folded angioplasty balloon catheter.
The stent-balloon assembly was posi-
tioned at the site of the intended inter-
vention, the sheath was withdrawn, and
the stent was deployed by means of in-
flation of the balloon. The stent diame-
ter was determined according to the
width of the uninvolved portion of the
vessel. In the patients randomized to
undergo PTA and selective stent place-
ment, PTA was performed according to
standard techniques (4). When elastic
recoil or inappropriate results at an-
giography were found after angioplasty,
larger balloon inflation and larger bal-
loons were applied. When a hemody-
namically significant gradient of greater
than 10 mm Hg was found after the final
PTA, stent placement was performed at
the same session, irrespective of evi-
dence of residual stenosis with angiog-
raphy. When evidence of residual ste-
nosis but no hemodynamically signifi-
cant gradient was found, we did not
perform stent placement. All patients
received anticoagulant medication (as-
pirin or oral anticoagulants) in accor-
dance with local guidelines or individual
preference of the referring physician,
independent of the type of intervention.
On the angiogram obtained during the
intervention, the radiologist noted the
angiographic characteristics of the iliac
artery lesions (Table 1). Short- and mid-
term technical and clinical results and
complications determined as long as 24
months after the procedure have al-
ready been published (2).
Follow-up Protocol
Follow-up assessments.—Data in all pa-
tients were collected before and directly
after intervention and at 3, 12, and 24
months thereafter, or as close to these
dates as logistically possible. A final col-
lection of data was conducted in 2002 (ie,
between 6 and 8 years after trial interven-
tion) by a few authors (W.M.K., J.S.,
and W.P.T.M.M.). All assessments
were equal for both treatment groups
and included assessment of symptoms,
measurement of ABI at rest, and color
duplex US of the treated iliac artery seg-
ment (left or right; common or external
iliac artery). Symptoms were recorded
according to the Fontaine classification
(Table 2). We did not use the Ruther-
ford classification (classification of the
Society of Vascular Surgery and the In-
ternational Society of Cardiovascular
Surgery [5]), which combines symp-
toms and ABI, because in the DIST
study, we experienced that use of the
Rutherford classification leaves about
one-third of the patients unclassifiable
at short- and midterm follow-up. With
the Rutherford classification, the classi-
fication of patients with PAD is per-
formed in a theoretical way, whereas
with the Fontaine classification, classifi-
cation can be performed clinically for all
patients.
To prevent patients from dropping
out at the final follow-up, patients were
offered a home visit in case they were
Table 1
Patient and Angiographic Characteristics at Baseline and after Treatment
Characteristic Primary Stent Placement PTA and Selective Stent Placement




Age (y)* 58 11 58 10
Fontaine classification†
I 4 (3) 5 (4)
II 132 (92) 120 (88)
III and/or IV 7 (5) 11 (8)
ABI at rest* 0.75 0.18 0.77 0.18
Location†
Common iliac artery 106 (74) 93 (68)
External iliac artery 37 (26) 43 (32)
Percentage of stenosis at angiography†
50% stenosis 9 (6) 11 (8)
50% stenosis 119 (83) 113 (83)
100% or total occlusion 15 (10) 12 (9)
Length of stenosis†
2 cm 83 (58) 74 (54)
2–10 cm 60 (42) 62 (46)
Runoff patency†
Occlusion of superficial femoral
artery 23 (16) 24 (18)
Occlusion of deep femoral artery 8 (6) 14 (10)
Stent placement† 139 (97)‡ 55 (40)§
Direct results of treatment
Residual stenosis50% on
angiogram after treatment† 1 (1) 4 (3)
ABI at rest* 0.94 0.20 0.96 0.24
Peak systolic velocity ratio* 1.2 0.9 1.3 0.6
* Data are the mean  standard deviation.
† Data are numbers of patients. Numbers in parentheses are percentages.
‡ Protocol violation and denial of primary stent placement occurred in four patients.
§ Denial of selective stent placement occurred in six patients; inappropriate stent placement, in five patients.
Table 2






III Pain at rest
IV Critical ischemia, ulceration,
or gangrene
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unable to come to the hospital, and this
visit included color duplex US per-
formed with a portable unit.
Reinterventions.—The trial did not
stipulate the criteria for or the manner
in which to reintervene. Treatment of
recurrent stenosis or of symptoms of
PAD detected at follow-up examinations
was the choice of the clinician and the
patient. Five years after treatment, we
recorded endovascular and surgical re-
interventions for the iliac artery seg-
ment (either common iliac artery or ex-
ternal iliac artery) that was treated in
the DIST study after we consulted the
general practitioner and the referring
clinician (6).
Quality-of-Life Assessments
Quality of life was measured with the
RAND 36-Item Health Survey 1.0 (7),
which refers to the patient’s health over
the previous 4 weeks. Quality of life was
assessed by means of questionnaires ad-
ministered over the telephone before
treatment and at 1, 3, 12, and 24
months after treatment (University of
Groningen). The 5-year measurement
was assessed by means of the same
questionnaires sent to the patients by
regular mail (W.M.K., W.P.T.M.M.).
The RAND 36-Item Health Survey is
equivalent to the Medical Outcomes
Study Short Form 36 and includes nine
health dimensions. For each dimension,
responses to items are summed and
scores are converted on a 0–100 scale,
in which 100 indicates optimal function-
ing or well-being.
Definition of Long-term Outcome
Symptomatic success was defined as an
increase of at least one Fontaine grade
during the whole follow-up period com-
pared with that at the pretreatment as-
sessment. Hemodynamic success was
defined as an increase of the ABI of 0.10
or more during the whole follow-up pe-
riod compared with the value at the pre-
treatment assessment. Patency of the
(common or external) iliac artery seg-
ment initially treated in the DIST study
was defined as a peak systolic velocity
ratio of less than 2.5 at duplex US (8)
during the whole follow-up period. Re-
intervention was defined as any surgical
or endovascular intervention for PAD
that involved the iliac artery segment
that was treated in the DIST study. We
chose the whole common iliac artery or
the whole external iliac artery that was
treated as the site of iliac patency or
reintervention, and not only the part in
which a stent was placed or the part
that was treated with PTA, because the
site treated with PTA alone is hard to
recognize. Also, in this way, the seg-
ments treated with either of the two
strategies were identical. Successful
outcome for quality of life was defined
as an increase of 15 or more in the score
on the RAND 36-Item Health Survey
during the whole follow-up period com-
pared with the score at the pretreat-
ment assessment.
Statistical Analysis
We analyzed data according to the in-
tention-to-treat principle, which implies
that we did not exclude any of the 279
patients after randomization. Further-
more, the reported outcomes are sec-
ondary results, because we did not ex-
clude patients after failure or reinter-
vention. For the analyses, we used one
lesion (the least favorable one) per pa-
tient. Symptomatic success, hemody-
namic success, patency, and reinterven-
tion were quantified with calculation of
the hazard ratios (HRs) and corre-
sponding 95% confidence limits (CLs).
Table 3
Available Data in Living Patients at Inclusion and during Follow-up
Data
No. of Patients with
Primary Stent
Placement




Symptom assessment results 143/143 (100) 136/136 (100)
ABI measurements 135/143 (94) 124/136 (91)
Duplex US results for iliac arteries 81/143 (57) 72/136 (53)
Quality-of-life assessment results 128/143 (90) 121/136 (89)
At follow-up
1 Month after treatment
Quality-of-life assessment results 126/143 (88) 119/136 (88)
3 Months after treatment
Symptom assessment results 138/143 (97) 125/136 (92)
ABI measurements 137/143 (96) 126/136 (93)
Duplex US results for iliac arteries 126/143 (88) 120/136 (88)
Quality-of-life assessment results 124/143 (87) 116/136 (85)
12 Months after treatment
Symptom assessment results 112/142 (79) 107/134 (80)
ABI measurements 118/142 (83) 112/134 (84)
Duplex US results for iliac arteries 109/142 (77) 107/134 (80)
Quality-of-life assessment results 118/142 (83) 104/134 (78)
24 Months after treatment
Symptom assessment results 92/141 (65) 91/131 (69)
ABI measurements 107/141 (76) 99/131 (76)
Duplex US results for iliac arteries 96/141 (68) 85/131 (65)
Quality-of-life assessment results 103/141 (73) 98/131 (75)
5 Years after treatment
Quality-of-life assessment results 91/129 (71) 89/116 (77)
6–8 Years after treatment
Symptom assessment results 95/118 (81) 80/110 (73)
ABI measurements 101/118 (86) 85/110 (77)
Duplex US results for iliac arteries 109/118 (92) 90/110 (82)
Note.—Numerators indicate the number of patients who attended a follow-up session. The denominators decreased from
inclusion to 6–8 years after treatment because some patients died. Numbers in parentheses are percentages.
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Kaplan-Meier curves are presented for
graphic comparison. The time to event
was set as the date of the clinical assess-
ment for symptomatic and hemody-
namic success and patency, as the date
of interview for quality of life, and as the
actual date of intervention for the analy-
ses of reintervention. Quality-of-life as-
sessment scores were calculated, and dif-
ferences between the two treatment arms
were tested by calculating HRs and 95%
CLs. Also, data of age-matched controls
were obtained from published literature
on 1063 randomly chosen Dutch persons
(9). We compared quality-of-life assess-
ment scores 5 years after treatment for
the two treatment groups with those of
the age-matched controls by using the
Student t test. Statistical tests were per-
formed with statistical software (SPSS
10.0; SPSS, Chicago, Ill) by several au-
thors (W.M.K., Y.v.d.G., E.B., F.L.M.,
W.P.T.M.M.) and a statistician. Evalua-
tion and interpretation of results was per-
formed by all authors.
All of the previously mentioned sur-
vival analyses were also performed in
the patients treated with PTA alone ver-




All but one of the 279 patients under-
went at least one follow-up examina-
tion. One patient was lost to follow-up.
Twenty-six patients (eight treated with
primary stent placement; 18 treated
with PTA and selective stent placement)
did not want to undergo the last fol-
low-up examination: Eleven patients re-
fused because of health reasons other
than PAD (Alzheimer disease, stroke,
cancer), and 15 patients refused be-
cause of personal reasons. Six patients
(other than the 26 who refused to un-
dergo the last follow-up examination)
had just undergone a routine clinical ex-
amination that included duplex US of
the iliac arteries, and we used the re-
sults of that examination for this study.
A further 13 patients (11 treated with
primary stent placement and two
treated with PTA and selective stent
placement) underwent their last fol-
low-up examination at their home. In 12
patients, this was so because of health
reasons; and in one patient, because of
his busy schedule. Available data are
given in Table 3. The mean duration
until the last follow-up examination or
death was 6.3 years  1.8 (standard
deviation), with a range of 0.7–8.6
years, for the patients with primary
stent placement and 5.7 years  2.2,
with a range of 0.3–8.7 years, for the
patients with PTA and selective stent
placement (P  .01).
During this follow-up period, in the
group with primary stent placement, 25
(17%) of 143 patients died, whereas in
the group with PTA and selective stent
placement, 26 (19%) of 136 patients
died (HR  1.3; 95% CLs: 0.7, 2.2) (6).
Table 4
Results of Follow-up Assessments per Lesion in Both Treatment Groups
Assessment Primary Stent Placement




I 88/138 (64) 85/125 (68)
II 49/138 (36) 40/125 (32)
III and/or IV 1/138 (1) 0/125 (0)
ABI measurement* 0.96 0.18 0.96 0.21
Occlusion at duplex US 1/126 (1) 1/120 (1)
Peak systolic velocity ratio* 1.3 0.9 1.5 0.6
Reinterventions† 2/143 (1) 1/136 (1)
At 12 months
Fontaine classification
I 72/112 (64) 72/107 (67)
II 40/112 (36) 35/107 (33)
III and/or IV 0/112 (0) 0/107 (0)
ABI measurement* 0.94 0.19 0.98 0.18
Occlusion at duplex US 0/109 (0) 0/107 (0)
Peak systolic velocity ratio* 1.5 1.0 1.6 0.8
Reinterventions† 5/142 (4) 4/134 (3)
At 24 months
Fontaine classification
I 59/92 (64) 56/91 (62)
II 33/92 (36) 34/91 (37)
III and/or IV 0/92 (0) 1/91 (1)
ABI measurement* 0.91 0.21 1.0 0.19
Occlusion at duplex US 0/96 (0) 0/85 (0)
Peak systolic velocity ratio* 1.7 0.9 1.8 1.0
Reinterventions† 8/141 (6) 2/131 (2)
At 6–8 years
Fontaine classification
I 31/90 (34) 38/78 (49)
II 45/90 (50) 27/78 (35)
III and/or IV 14/90 (16) 13/78 (17)
ABI measurement* 0.90 0.20 0.96 0.22
Occlusion at duplex US 5/109 (5) 10/90 (11)
Peak systolic velocity ratio* 1.9 1.6 1.7 1.1
Reinterventions† 12/118 (10) 21/110 (19)
Note.—Unless otherwise indicated, data are numbers of lesions. The denominators correspond to the numerators in Table 3
(ie, available data). Numbers in parentheses are percentages.
* Data are the mean  standard deviation.
† Data are numbers of patients. Numbers in parentheses are percentages.
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All results of follow-up assessments
per lesion are presented in Table 4.
Symptomatic Success
At the follow-up assessment at 3
months, symptomatic success was
achieved in about 70% of the patients in
both treatment groups (Fig 1). At the
final follow-up assessment, 59 (66%) of
90 of the patients treated with primary
stent placement and 40 (51%) of 78 of
the patients treated with PTA and selec-
tive stent placement still had symptoms
of PAD. With the Cox survival analysis,
an HR of 0.8 (95% CLs: 0.6, 1.0) was
calculated, and this result was in favor
of the lesions treated with PTA and se-
lective stent placement (Fig 1).
Hemodynamic Success
The mean  standard deviation for ABI
increased from 0.75  0.18 before treat-
ment to 0.94  0.20 after treatment and
then decreased to 0.90 0.20 at the final
follow-up for the patients with primary
stent placement. For the patients treated
with PTA and selective stent placement,
the ABI increased from 0.77  0.18 be-
fore treatment to 0.96 0.24 after treat-
ment and remained as 0.96  0.22 at the
final follow-up. Hemodynamic success
was achieved in about 70% of the patients
in both groups at the 3-month follow-up
assessment (Fig 2).With the Cox survival
analysis, an HR of 0.9 (95%CLs: 0.7, 1.3)
was calculated.
Patency
Iliac patency decreased from 97%
(122 of 126 patients) at 3 months after
treatment to 83% (90 of 109 patients)
at the final follow-up in the patients
with primary stent placement and
from 94% (113 of 120 patients) to
74% (67 of 90 patients) in the patients
treated with PTA and selective stent
placement. The HR was 1.3 (95% CLs:
0.8, 2.1) (Fig 3).
Reintervention
Twenty-five (17%) of 143 patients
treated with primary stent placement
needed reintervention in the iliac artery
segment that was initially treated in the
DIST study because of symptoms or
signs (in noninvasive measurements) of
restenosis. In the group that was
treated with PTA and selective stent
placement, 28 (21%) of 136 patients
needed reintervention (HR  1.1; 95%
CLs: 0.6, 1.9). There was no difference
in the number of endovascular and sur-
gical procedures between the two treat-
ment groups (6).
Quality of Life
All RAND 36-Item Health Survey scores
increased substantially in both groups
after treatment (3) (Table 5). At 5 years
after treatment, all scores, except the
score for general health perception,
were still markedly higher than they
were before treatment in both groups.
Survival analyses showed no differences
in RAND 36-Item Health Survey scores
between the two treatment groups over
the whole follow-up period.
Whenwe compared the quality-of-life
scores of the two treatment groups 5
years after treatment with data in age-
matched controls from the literature, pa-
tients treated with PTA and selective
stent placement had scores that were
equally as high as the age-matched con-
trols for all dimensions. On the other
hand, patients treated with primary stent
placement had scores that were substan-
tially lower for physical functioning, phys-
ical role functioning, vitality, bodily pain,
and general health perception, whereas
scores for emotional role functioning, so-
cial functioning, mental health, and health
change were equivalent to those in age-
matched controls (Fig 4).
PTA Alone versus Stent Placement
When we compared the patients
treated with selective or primary stent
placement versus the patients treated
with PTA alone, we could not show any
difference with regard to symptomatic
and hemodynamic success, iliac pa-
Figure 1
Figure 1: Kaplan-Meier survival curves for symptomatic success. Solid line signifies primary stent place-
ment (101 of 143 patients); and dotted line, PTA with selective stent placement (80 of 134 patients).
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tency, and quality-of-life assessment
scores. Also, iliac reinterventions and
ipsilateral interventions were not differ-
ent for patients with and without stent
placement.
Discussion
Selective stent placement for iliac artery
lesions results in a better preservation
of symptomatic success in the long
term, without a difference in the results
for hemodynamic success, iliac artery
patency, and quality of life. Therefore,
selective stent placement should be the
treatment of preference for iliac artery
lesions.
Although the data did not support a
difference between treatment groups
for iliac artery patency and ABI, PTA
and selective stent placement should be
the treatment of choice over primary
stent placement. Besides better results
for symptomatic success, selective stent
placement has several other advantages
over primary stent placement. Long-
term quality of life of patients treated
with selective stent placement was not
different from that in age-matched con-
trols, while patients treated with pri-
mary stent placement had lower scores.
Another advantage is that use of PTA
and selective stent placement results in
a considerable cost savings, as only 40%
of the patients actually needed stent
placement and thus required only a
small number of the stents needed in
the strategy of primary stent placement.
Further, it is usually preferred in medi-
cine both by patients and physicians not
to use foreign bodies unnecessarily. In
this study, we showed that primary
stent placement is not necessary.
Despite the technically successful
treatment in both groups, as is apparent
from the long-term patency results, the
patients treated with PTA and selective
stent placement tended to have a clini-
cally better outcome than did the pa-
tients treated with primary stent place-
ment. Because patients were random-
ized for treatment, we assumed that
predictors of outcome were equally dis-
tributed over the two treatment groups,
and the differences between the groups
in the long term could only be explained
by the difference in treatment. The ten-
dency toward fewer symptoms in the
group with selective stent placement
cannot be explained by better patency
or hemodynamic success. We do not
know the reason for this more rapid
deterioration of symptoms in patients
treated with primary stent placement.
The deterioration may be caused by the
breakdown of stent material. Also, al-
lergic reactions to metal released from
stents have been proposed as the trig-
gering mechanisms for in-stent resteno-
sis (10). This difference, however, was
not found when we compared patients
treated with PTA alone versus patients
treated with primary or selective stent
placement, and this finding indicates
that some patients benefit from selec-
tive stent placement (in this study, that
meant that the stent was placed when a
residual pressure gradient of 10 mm
Hg was present). This late chronic ef-
fect of primary stent placement, to our
knowledge, has not been demonstrated
before in studies in patients with iliac
artery disease, as there have been no
other randomized trials with long-term
follow-up of peripheral arterial lesions
in which primary stent placement was
compared with PTA and selective stent
placement. Only in randomized trials
with long-term follow-up can the actual
differences in outcome of patients
treated with primary stent placement
versus those treated with PTA and se-
lective stent placement be detected. Co-
hort studies provide biased evidence if
treatments are compared.
To the best of our knowledge, this
study is the first in which two endovas-
cular treatment methods for iliac artery
disease were compared in a randomized
way and with long-term follow-up. We
presented a complete spectrum with
both subjective and objective results.
Figure 2
Figure 2: Kaplan-Meier survival curves for hemodynamic success measured with ABI. Solid line signifies
primary stent placement (81 of 136 events); and dotted line, PTA with selective stent placement (68 of 126
events).
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Data about cardiovascular morbidity
and mortality in these patients have
been published before (6). Some studies
about endovascular treatment of the il-
iac arteries with a follow-up of 4 years
or longer have been published (11–16).
Researchers in most of these studies re-
ported results for iliac patency, and
these results seem to be in accordance
with our outcomes: 72%–92% second-
ary iliac artery patency after a follow-up
of 4.0–7.5 years. The definition of suc-
cessful patency, however, was dissimi-
lar in the different studies; in none of
the studies were solely duplex US re-
sults used for defining patency, and in
most of them, clinical success was in-
corporated within the definition of suc-
cessful patency.
In none of these studies did re-
searchers report the results for assess-
ment of symptomatic success separately
from those for assessment of technical
success, as we did. Also in none of the
studies did the researchers report the
results for quality-of-life evaluation. In a
meta-analysis in which PTA was com-
pared with primary or selective stent
placement for iliac artery disease, it was
found that stent placement had lower
long-term failure rates (17). In none of
the studies that were included in this
meta-analysis were the analyses ran-
domized.
In studies about the quality of life in
patients with PAD, the endovascular
treatment was not randomized, and in
none of these studies was the follow-up
period longer than 2 years (18–20).
Chetter et al (21) found that PTA of iliac
artery lesions resulted in immediate im-
provement of quality of life and that the
quality of life approached the level of
that of age-matched controls. It was
found that patency and ABI had no ef-
fect on quality of life but that the pres-
ence of symptoms of PAD had negative
effects on the quality of life (19,22,23).
Physical functioning and bodily pain
contributed most to the reduction of
quality of life in patients with claudica-
tion (24,25). These findings seem to be
in accordance with our findings; in our
study, the patients treated with PTA
and selective stent placement had bet-
ter preservation of symptomatic success
and also had higher scores for quality-
of-life assessment compared with those
in age-matched controls.
We noticed a preference for pri-
mary stent placement—not only for the
iliac artery and more peripheral arter-
ies but also for the coronary, carotid,
and renal arteries—in clinical practice
all over the world. There is no convinc-
ing evidence, however, that primary
stent placement is actually better than
PTA and selective stent placement in
any of these arteries. As for the coro-
nary arteries, there have been several
randomized trials in which primary
stent placement was compared with
PTA with selective stent placement (26–
30). The longest follow-up period in
these studies was 5 years (26). The gen-
eral conclusion of these studies is that
PTA with selective stent placement is as
good as primary stent placement in re-
gard to symptoms of angina, myocardial
infarction, and survival. In the long
term, however, primary stent place-
ment results in fewer reinterventions in
the target lesion. The majority of cardi-
ologists have therefore chosen primary
stent placement, and they have also
done so because stent placement is an
easy and fast procedure, unlike the
complex procedure that is necessary to
decide whether selective stent place-
ment after PTA is needed (31,32). In
the Dutch Iliac Stent Trial, the criterion
for selective stent placement was based
on the presence of a pressure gradient
over the stenosis. Determination of this
gradient is complex and time consum-
ing. Since we have shown that selective
stent placement leads to better symp-
tomatic success in the long term, it is
the treatment of choice for the iliac ar-
teries. Difficulties in measuring the
pressure gradient should be dealt with.
Also, in the carotid and renal arteries,
Figure 3
Figure 3: Kaplan-Meier survival curves for iliac patency measured with duplex US. Solid line signifies
primary stent placement (33 of 139 patients); and dotted line, PTA with selective stent placement (38 of 130
patients).
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primary stent placement is in vogue be-
cause of the ease and quickness of the
procedure. Here, too, no sound evi-
dence is available that this method is
actually better, as there are no random-
ized trials in which PTA with selective
stent placement was compared with pri-
mary stent placement.
About half of the patients in both
treatment groups of the DIST study had
recurrence or progression of symptoms
of PAD in the long term (and this was
more extensive in the patients with pri-
mary stent placement). In a limited
number of patients, this recurrence or
progression of symptoms could be
caused by recurrence of the iliac artery
stenosis; however, this cause cannot ex-
plain all cases of recurrence or progres-
sion of symptoms, as the iliac artery
patency is high. Progression of athero-
sclerotic disease in the more peripheral
arteries is a more valid explanation of
the recurrence or progression of PAD
symptoms. Patients ought to be in-
formed about their high risk of lasting
or recurrent symptoms after endovas-
cular treatment. Secondary preventive
measures, such as treatment of risk fac-
tors and exercise training, must be in-
tensive, and, when possible and neces-
sary, further invasive treatment must
be considered.
Figure 4
Figure 4: Graphs show RAND 36-Item Health Survey scores for (a) physical functioning and (b) bodily pain in two treatment groups of the DIST study and in age-
matched controls. Solid line signifies group with primary stent placement; dotted line, group with PTA and selective stent placement; and dashed and dotted line, age-
matched controls. At long term, scores of patients treated with selective stent placement were not different from data in age-matched controls, whereas patients with pri-
mary stent placement had lower scores.
Table 5
RAND 36-Item Health Survey Scores at Baseline and during Follow-up
Dimension










Physical functioning 39.6 18.9 73.0 25.2 61.0 27.3 42.1 20.4 72.9 25.4 71.2 26.1
Physical role functioning 27.1 36.3 58.5 44.3 61.2 41.2 32.0 40.5 55.9 45.2 70.0 39.2
Emotional role functioning 59.9 44.5 72.2 40.6 80.7 35.3 54.8 44.7 66.4 41.3 86.4 28.2
Social functioning 63.8 27.0 77.8 25.9 80.4 25.1 68.5 28.2 76.4 26.0 80.2 23.6
Bodily pain 50.3 22.2 75.8 24.6 67.8 25.8 49.3 24.6 67.5 27.8 77.5 24.2
General health perception 56.7 21.0 63.2 22.4 53.7 21.1 53.5 22.8 57.2 21.5 59.7 24.4
Mental health 70.4 21.4 75.3 20.2 75.2 17.9 69.1 21.9 74.2 19.2 76.7 17.3
Vitality 50.9 23.3 62.2 23.5 61.1 20.6 52.6 21.5 61.3 21.9 64.3 20.6
Health change 30.9 22.5 71.2 27.4 47.9 22.1 31.2 21.0 62.4 30.0 47.5 18.9
Note.—Values are the mean  standard deviation.
VASCULARAND INTERVENTIONALRADIOLOGY:Dutch Iliac Stent Trial Klein et al
742 Radiology: Volume 238: Number 2—February 2006
This study had some limitations that
need to be discussed. The finding that
patients treated with primary stent
placement on average had a slightly
longer follow-up time than did patients
treated with PTA and selective stent
placement could possibly have influ-
enced the outcome of the study. The
longer follow-up might have led to bi-
ased results, even with follow-up time
being taken into account with survival
analyses. Patients in both treatment
groups were subject to the same fol-
low-up protocol; however, they were
aware as to whether or not they had
been treated with PTA alone or stent
placement (2), and this awareness
could have caused a difference in atten-
dance of follow-up assessments.
Another limitation was that we used
the RAND 36-Item Health Survey ques-
tionnaire, which is not disease specific.
At the time the DIST study was started,
this questionnaire was the most widely
used and best available for quality-of-life
assessment, and it was validated and
translated into Dutch. Also, researchers
in other studies about the quality of life
in patients with PAD used nondisease-
specific questionnaires (18–20,23), and
they too measured an effect of treat-
ment. A disease-specific questionnaire
could enable a more detailed assess-
ment of the effect of treatment on the
quality of life in these patients.
A possible limitation was that the
questionnaire was completed with a
telephone interview until 24 months af-
ter treatment. At 5 years, a paper ver-
sion was sent to the patients’ homes.
This difference may have caused pa-
tients in both groups to give different
answers. Patients were informed about
the treatment they had undergone. Pa-
tients’ knowledge of whether or not they
had a stent may have caused different
scores on the RAND 36-Item Health
Survey and could have resulted in some
bias across treatment groups.
We conclude that, for patients with
iliac artery disease, treatment with PTA
and selective stent placement is at least
as good as treatment with primary stent
placement in the long term. Selective
stent placement tended to lead to a bet-
ter preservation of symptomatic success
and quality of life. Therefore, selective
stent placement should be the preferred
method.
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